Status:
COMPLETED
Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream
Lead Sponsor:
Trans Tasman Radiation Oncology Group
Collaborating Sponsors:
3M
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the...
Detailed Description
Skin reactions are a common and undesirable result of radiation treatment. Preventative measures are often used although there are few controlled trials. Commonly employed agents for established react...
Eligibility Criteria
Inclusion
- Ages 18 or more years
- Post total mastectomy
- Planned dose at least 45 Gy in 25 fractions
- ECOG 0-2
- Able to attend weekly during treatment for review and photo and for up to 6 weeks after radiotherapy
- Patients capable of childbearing using adequate contraception
- Written informed consent
Exclusion
- Previous radiotherapy to the chest wall to be treated
- Macroscopic cutaneous involvement by malignancy at time of radiotherapy
- Known allergy to product contents
- Patients who are pregnant or lactating.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
333 Patients enrolled
Trial Details
Trial ID
NCT00193908
Start Date
March 1 2004
End Date
October 1 2008
Last Update
May 14 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
St George Hospital
Kogarah, New South Wales, Australia, 2217
2
Liverpool Hospital
Liverpool, New South Wales, Australia, 1871
3
Calvary Mater Newcastle
Newcastle, New South Wales, Australia, 2298
4
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031